Efficacy of mFOLFOX6 with bebacizumab or cetuximab based on K-ras status for unresectable hepatic metastasis of colorectal cancer

Efficacy of mFOLFOX6 with bebacizumab or cetuximab based on K-ras status for unresectable hepatic metastasis of colorectal cancer - Efficacy of mFOLFOX6 with bebacizumab or cetuximab based on K-ras status for unresectable hepatic metastasis of colorectal cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004310

Enrollment

Registered

2010-10-04

Start date

2010-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Unresectable hepatic metastasis of colorectal cancer

Interventions

mFOLFOX6+bev or mFOLFOX6+cet

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. colorectal cancer histologically confirmed 2. K-ras status confirmed 3. unresectable hepatic metastasis 4. Liver-specific metastasis or resectable extrahepatic metastasis 5. adequate bone marrow, hepatic, and renal function

Exclusion criteria

Exclusion criteria: 1. Brain metastasis, brain tumor 2. symptomatic cerebrovascular disease 3. active bleeding 4. uncontrolled hypertention etc.

Design outcomes

Primary

Measure	Time frame
The ratio of R0 resection or clinical CR	—

Secondary

Measure	Time frame
Safety, The ratio of R0 hepatic resection, overall response rate, pathological response rate, progression free survival, 2-year survival rate, Compliance of initial regimen, relative dose intensity	—

Countries

Japan

Contacts

Public ContactKojiro Nakamura

Kyoto University Dept of Hepatobiliarypancreatic and transplantation surgery

shiryou@kuhp.kyoto-u.ac.jp075-751-3608

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026